A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT03219333 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Transitional Cell
Urinary Bladder Neoplasms
Urologic Neoplasms
Renal Pelvis Neoplasms
Urothelial Cancer
Ureteral Neoplasms
Urethral Neoplasms

Interventions

DRUG: Enfortumab vedotin

Sponsor

Astellas Pharma Inc

Collaborators

[object Object]